Cardiovascular safety is a leading cause of drug attrition and often emerges too late, when the costs of failure are at their highest. For drug discovery scientists, identifying cardiac liabilities early in the development pipeline is not only a scientific imperative but also a strategic necessity. Early detection enables informed decision-making, more efficient use of resources, and the opportunity to refine or deprioritise candidates before significant investment in preclinical or clinical development.

Recent updates to FDA guidance on nonclinical cardiovascular safety testing highlight an important shift in regulatory expectations. In this changing environment, the use of robust, human-relevant in vitro models is becoming increasingly important for assessing cardiac risk and supporting the development of safer medicines.

This webinar will explore two key approaches to cardiovascular safety screening in discovery.